Abstract 3400
Background
Dermatologic toxicities related to radiotherapy treatments affect substantially the patient’s quality of life. It is well stated that the causes are closely related to the radiotherapy treatment technique and to the individual genetic variation factors. More specifically, the received by each skin point is suggested as one of the most important among those causes. But there are still no studies proving this correlation as the skin radiation dose is only assessed within a 15% uncertainty using the current feasible procedures in a common department. On the contrary, we would expect a good correlation, even more, stating a skin-toxicities predicting method by assessing the skin dose using a feasible 5% uncertainty procedure.
Methods
Prospective transversal study of breast cancer patients receiving normofractionated external radiation therapy, without bolus compensator. This study uses a non-invasive innovative method to obtain accurate skin radiation doses based in a Software as a Service and radiochromic films.The prescribed dose, the dose report from the Treatment Planning System as well as its class and version, the irradiated volume and measured skin dose and extension by means of this innovative method at fractions 1, 2, 3, 15, 25 and end of treatment will be collected and correlated to acute skin toxicities of the patients. This will be performed using the Radiation Therapy Group gradation during the nurse visit ongoing- and post-treatment till 90 days since its ending.
Results
This study will state a skin radiation dose – toxicity relationship for breast cancer patients as a result of a Pearson correlation coefficient analysis for each pair of variables.
Conclusions
The most common action in a nurse care plan is to treat signs and symptoms of the dermatologic toxicities but its causes are excluded, mainly due to a lack of knowledge. This study tries to formally state the skin radiation dose – toxicities relationship and, furthermore, the theoretical bases to determine and predict the skin radiation toxicities grade for each treatment. Even more, this will become a useful tool to improve the treatment success probability as well as empowering nursing for designing more accurate patient-specific radiotherapy care plans.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract